Enterprise Value

-81.86M

Cash

223.6M

Avg Qtr Burn

-31.79M

Short % of Float

4.03%

Insider Ownership

1.02%

Institutional Own.

93.61%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 2

Update

Camonsertib (RP-3500) Details
Cancer, Solid tumor/s

Phase 1/2

Update

Phase 1

Data readout

Phase 1

Data readout

RP-6306 Monotherapy Details
Cancer, Solid tumor/s

Phase 1

Data readout

Phase 1

Data readout